A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

PHASE4CompletedINTERVENTIONAL

Enrollment

201

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

May 25, 2023

Study Completion Date

May 25, 2023

Conditions

Parkinson Disease

Interventions

DRUG

Safinamide Mesilate

Safinamide Mesilate oral tablets.

Trial Locations (20)

Eisai Site #11, Busan

Eisai Site #20, Busan

Eisai Site #3, Busan

Eisai Site #16, Daegu

Eisai Site #2, Daegu

Eisai Site #19, Daejeon

Eisai Site #10, Gwangju

Eisai Site #12, Gyeonggi-do

Eisai Site #15, Gyeonggi-do

Eisai Site #17, Gyeonggi-do

Eisai Site #5, Gyeonggi-do

Eisai Site #14, Incheon

Eisai Site #13, Seoul

Eisai Site #18, Seoul

Eisai Site #1, Seoul

Eisai Site #4, Seoul

Eisai Site #6, Seoul

Eisai Site #7, Seoul

Eisai Site #8, Seoul

Eisai Site #9, Seoul

All Listed Sponsors

lead

Eisai Korea Inc.

INDUSTRY